Biological activity of 26-succinylbryostatin 1

Gary S. Bignami, Fred Wagner, Paul G. Grothaus, Pradip Rustagi, Dana E. Davis, Andrew Kraft

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Bryostatin 1, a macrocyclic lactone, has undergone phase I trials as an anticancer agent. Because of the lipid solubility of this compound it must be delivered either in ethanol or in a PET formulation. During the trial, these vehicles caused a large number of treatment-related side effects. We have synthesized the triethanolamine salt of 26-succinylbryostatin 1 and find that this compound is approx. 100-fold more water soluble than bryostatin 1. Because of the potential for clinical use, we have evaluated the biologic activity of this compound. We find that in a concentration-dependent manner 26-succinylbryostatin 1 is capable of activating protein kinase C (PKC) in vitro and displacing [3H]PDBu from PKC. However, at all concentrations tested the activity was less than the parent compound bryostatin 1. Addition of bryostatin 1 but not 26-succinylbryostatin 1 to U937 leukemic cells in culture stimulated a drop in cytosolic PKC, secondary to translocation of PKC to the membrane. Although 26-succinylbryostatin 1 did not stimulate a drop in the cytosolic levels of PKC, addition to U937 cells activated transcription from an AP-1 enhancer construct and c-Jun protein phosphorylation in a similar fashion to bryostatin 1 and differentiation of U937 cells. Unlike bryostatin 1, 26-succinylbryostatin 1 was unable to cause aggregation of human platelets. Although injection of bryostatin-1 into mice carrying B16 melanoma inhibits tumor growth, there was no significant inhibition of melanoma growth when identical doses of 26-succinylbryostatin 1 were injected. Therefore, 26-succinylbryostatin 1 shares some but not all of the pharmacologic properties of bryostatin 1. This compound can activate protein phosphorylation without lowering cytosolic levels of PKC.

Original languageEnglish (US)
Pages (from-to)197-206
Number of pages10
JournalBBA - Molecular Cell Research
Volume1312
Issue number3
DOIs
StatePublished - Jul 24 1996
Externally publishedYes

Fingerprint

Protein Kinase C
U937 Cells
Phosphorylation
Proto-Oncogene Proteins c-jun
Experimental Melanomas
26-succinylbryostatin 1
bryostatin 1
Transcription Factor AP-1
Lactones
Growth
Platelet Aggregation
Antineoplastic Agents
Solubility
Melanoma
Ethanol
Cell Culture Techniques
Salts
Lipids
Injections
Membranes

Keywords

  • 26-Succinylbryostatin 1
  • Antitumor activity
  • PKC
  • PKC translocation

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Biophysics

Cite this

Bignami, G. S., Wagner, F., Grothaus, P. G., Rustagi, P., Davis, D. E., & Kraft, A. (1996). Biological activity of 26-succinylbryostatin 1. BBA - Molecular Cell Research, 1312(3), 197-206. https://doi.org/10.1016/0167-4889(96)00018-3

Biological activity of 26-succinylbryostatin 1. / Bignami, Gary S.; Wagner, Fred; Grothaus, Paul G.; Rustagi, Pradip; Davis, Dana E.; Kraft, Andrew.

In: BBA - Molecular Cell Research, Vol. 1312, No. 3, 24.07.1996, p. 197-206.

Research output: Contribution to journalArticle

Bignami, GS, Wagner, F, Grothaus, PG, Rustagi, P, Davis, DE & Kraft, A 1996, 'Biological activity of 26-succinylbryostatin 1', BBA - Molecular Cell Research, vol. 1312, no. 3, pp. 197-206. https://doi.org/10.1016/0167-4889(96)00018-3
Bignami GS, Wagner F, Grothaus PG, Rustagi P, Davis DE, Kraft A. Biological activity of 26-succinylbryostatin 1. BBA - Molecular Cell Research. 1996 Jul 24;1312(3):197-206. https://doi.org/10.1016/0167-4889(96)00018-3
Bignami, Gary S. ; Wagner, Fred ; Grothaus, Paul G. ; Rustagi, Pradip ; Davis, Dana E. ; Kraft, Andrew. / Biological activity of 26-succinylbryostatin 1. In: BBA - Molecular Cell Research. 1996 ; Vol. 1312, No. 3. pp. 197-206.
@article{4a99f31705b7400cbaf7c2013e749658,
title = "Biological activity of 26-succinylbryostatin 1",
abstract = "Bryostatin 1, a macrocyclic lactone, has undergone phase I trials as an anticancer agent. Because of the lipid solubility of this compound it must be delivered either in ethanol or in a PET formulation. During the trial, these vehicles caused a large number of treatment-related side effects. We have synthesized the triethanolamine salt of 26-succinylbryostatin 1 and find that this compound is approx. 100-fold more water soluble than bryostatin 1. Because of the potential for clinical use, we have evaluated the biologic activity of this compound. We find that in a concentration-dependent manner 26-succinylbryostatin 1 is capable of activating protein kinase C (PKC) in vitro and displacing [3H]PDBu from PKC. However, at all concentrations tested the activity was less than the parent compound bryostatin 1. Addition of bryostatin 1 but not 26-succinylbryostatin 1 to U937 leukemic cells in culture stimulated a drop in cytosolic PKC, secondary to translocation of PKC to the membrane. Although 26-succinylbryostatin 1 did not stimulate a drop in the cytosolic levels of PKC, addition to U937 cells activated transcription from an AP-1 enhancer construct and c-Jun protein phosphorylation in a similar fashion to bryostatin 1 and differentiation of U937 cells. Unlike bryostatin 1, 26-succinylbryostatin 1 was unable to cause aggregation of human platelets. Although injection of bryostatin-1 into mice carrying B16 melanoma inhibits tumor growth, there was no significant inhibition of melanoma growth when identical doses of 26-succinylbryostatin 1 were injected. Therefore, 26-succinylbryostatin 1 shares some but not all of the pharmacologic properties of bryostatin 1. This compound can activate protein phosphorylation without lowering cytosolic levels of PKC.",
keywords = "26-Succinylbryostatin 1, Antitumor activity, PKC, PKC translocation",
author = "Bignami, {Gary S.} and Fred Wagner and Grothaus, {Paul G.} and Pradip Rustagi and Davis, {Dana E.} and Andrew Kraft",
year = "1996",
month = "7",
day = "24",
doi = "10.1016/0167-4889(96)00018-3",
language = "English (US)",
volume = "1312",
pages = "197--206",
journal = "Biochimica et Biophysica Acta - Molecular Cell Research",
issn = "0167-4889",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Biological activity of 26-succinylbryostatin 1

AU - Bignami, Gary S.

AU - Wagner, Fred

AU - Grothaus, Paul G.

AU - Rustagi, Pradip

AU - Davis, Dana E.

AU - Kraft, Andrew

PY - 1996/7/24

Y1 - 1996/7/24

N2 - Bryostatin 1, a macrocyclic lactone, has undergone phase I trials as an anticancer agent. Because of the lipid solubility of this compound it must be delivered either in ethanol or in a PET formulation. During the trial, these vehicles caused a large number of treatment-related side effects. We have synthesized the triethanolamine salt of 26-succinylbryostatin 1 and find that this compound is approx. 100-fold more water soluble than bryostatin 1. Because of the potential for clinical use, we have evaluated the biologic activity of this compound. We find that in a concentration-dependent manner 26-succinylbryostatin 1 is capable of activating protein kinase C (PKC) in vitro and displacing [3H]PDBu from PKC. However, at all concentrations tested the activity was less than the parent compound bryostatin 1. Addition of bryostatin 1 but not 26-succinylbryostatin 1 to U937 leukemic cells in culture stimulated a drop in cytosolic PKC, secondary to translocation of PKC to the membrane. Although 26-succinylbryostatin 1 did not stimulate a drop in the cytosolic levels of PKC, addition to U937 cells activated transcription from an AP-1 enhancer construct and c-Jun protein phosphorylation in a similar fashion to bryostatin 1 and differentiation of U937 cells. Unlike bryostatin 1, 26-succinylbryostatin 1 was unable to cause aggregation of human platelets. Although injection of bryostatin-1 into mice carrying B16 melanoma inhibits tumor growth, there was no significant inhibition of melanoma growth when identical doses of 26-succinylbryostatin 1 were injected. Therefore, 26-succinylbryostatin 1 shares some but not all of the pharmacologic properties of bryostatin 1. This compound can activate protein phosphorylation without lowering cytosolic levels of PKC.

AB - Bryostatin 1, a macrocyclic lactone, has undergone phase I trials as an anticancer agent. Because of the lipid solubility of this compound it must be delivered either in ethanol or in a PET formulation. During the trial, these vehicles caused a large number of treatment-related side effects. We have synthesized the triethanolamine salt of 26-succinylbryostatin 1 and find that this compound is approx. 100-fold more water soluble than bryostatin 1. Because of the potential for clinical use, we have evaluated the biologic activity of this compound. We find that in a concentration-dependent manner 26-succinylbryostatin 1 is capable of activating protein kinase C (PKC) in vitro and displacing [3H]PDBu from PKC. However, at all concentrations tested the activity was less than the parent compound bryostatin 1. Addition of bryostatin 1 but not 26-succinylbryostatin 1 to U937 leukemic cells in culture stimulated a drop in cytosolic PKC, secondary to translocation of PKC to the membrane. Although 26-succinylbryostatin 1 did not stimulate a drop in the cytosolic levels of PKC, addition to U937 cells activated transcription from an AP-1 enhancer construct and c-Jun protein phosphorylation in a similar fashion to bryostatin 1 and differentiation of U937 cells. Unlike bryostatin 1, 26-succinylbryostatin 1 was unable to cause aggregation of human platelets. Although injection of bryostatin-1 into mice carrying B16 melanoma inhibits tumor growth, there was no significant inhibition of melanoma growth when identical doses of 26-succinylbryostatin 1 were injected. Therefore, 26-succinylbryostatin 1 shares some but not all of the pharmacologic properties of bryostatin 1. This compound can activate protein phosphorylation without lowering cytosolic levels of PKC.

KW - 26-Succinylbryostatin 1

KW - Antitumor activity

KW - PKC

KW - PKC translocation

UR - http://www.scopus.com/inward/record.url?scp=0030600229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030600229&partnerID=8YFLogxK

U2 - 10.1016/0167-4889(96)00018-3

DO - 10.1016/0167-4889(96)00018-3

M3 - Article

C2 - 8703988

AN - SCOPUS:0030600229

VL - 1312

SP - 197

EP - 206

JO - Biochimica et Biophysica Acta - Molecular Cell Research

JF - Biochimica et Biophysica Acta - Molecular Cell Research

SN - 0167-4889

IS - 3

ER -